News | December 12, 2024
Biocon Biologics recognized as Asia IP Elite for 2024 by IAM
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
Reaffirms Lupin’s commitment to sustainable resource management
In the near term, the company targets a 42% reduction in absolute Scope 1 and 2 emissions and Scope 3 emissions by FY2030
The product will be marketed by Dr. Reddy's
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Gross Profit stood at Rs. 36.02 crore compared to Rs. 20.42 crore during Q2FY24, a significant increase of 76.40%
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
He will join in place of Anil Arora, current President- Formulations Operations who will be superannuating in November, 2024
Subscribe To Our Newsletter & Stay Updated
